Sublingual Immunotherapy in Patients With Atopic Dermatitis

Inclusion Criteria:

• Patients of either sex ,aged from 18 to 60 years. Diagnosed of atopic dermatitis.
• Mild to moderate AD ( [SCORAD] 1O-40)
• The results of skin prick tests with dermatophagoides farinae allergen extracts preparation is positive(≥2+)
• Written informed consent by the subject or legal guardian.
• Female patients of child-bearing potential must be negative pregnant test on screening and use an appropriate method of contraception.

Exclusion Criteria:

• Dust mites are not the primary allergens.
• Pregnant, breastfeeding women or women planned to pregnant within 1 year.
• Have concurrent skin disease that it could interfere with the study evaluation.
• Were treated with antihistamines or topical therapy within 7 days of randomization.
• Have received systemic corticosteroids,leukotriene receptor antagonists or immunosuppressants within 4 weeks of randomization.
• Have received phototherapy (e.g. UVA, UVB) within 4 weeks of randomization.
• Have a history of immune suppressed diseases(malignant tumor or infection of HIV), autoimmune disease or tuberculosis.
• Patients with impaired liver function (aspartate aminotransferase and/ or alanine aminotransferase levels 1.5 times the upper limit of normal), impaired renal function(serum creatinine＞normal value) or other severe diseases.
• Bronchial asthma patients who need treatments with corticosteroids and or β agonists(including injection, oral administration or inhalation) regularly.
• Patients who need to take β-blockers during research.
• Have received investigational drugs within 3 months prior to randomization or planned use of other investigational drugs during participation in this study.
• Have received immunotherapy with dust mite preparation within 3 years prior to randomization.
• Patients with severe mental disorders.